Abacavir/lamivudine combination in the treatment of HIV: a review

Abacavir/lamivudine combination in the treatment of HIV: a review

Geetha Sivasubramanian1, Emmanuel Frempong-Manso2, Rodger D MacArthur11Division of Infectious Diseases, Wayne State University, Detroit, MI, USA; 2University of Pittsburgh Medical Center, Shadyside Hospital, Pittsburgh, OH, USAAbstract: Abacavir has been at the center of research and clinical intere...

Full description

Bibliographic Details
Main Authors:	Geetha Sivasubramanian, Emmanuel Frempong-Manso, Rodger D MacArthur
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-02-01
Series:	Therapeutics and Clinical Risk Management
Online Access:	http://www.dovepress.com/abacavirlamivudine-combination-in-the-treatment-of-hiv-a-review-a4006

Similar Items

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
by: Santiago Moreno Guillen, et al.
Published: (2017-09-01)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
by: Cruciani M, et al.
Published: (2015-02-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Sharlene Ho, et al.
Published: (2020-05-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia
by: Elisabeth Petit, et al.
Published: (2018-01-01)

Simultaneous Determination of Lamivudine, Zidovudine and Abacavir in Tablet Dosage Forms by RP HPLC Method
by: D. Anantha Kumar, et al.
Published: (2010-01-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
by: Julián Olalla, et al.
Published: (2018-10-01)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
by: Squires KE, et al.
Published: (2017-03-01)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
by: Nadia Galizzi, et al.
Published: (2018-01-01)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
by: Jesús Troya, et al.
Published: (2018-01-01)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
by: Torsak Bunupuradah, et al.
Published: (2015-07-01)

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
by: Bagella P, et al.
Published: (2019-05-01)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
by: Jesús Troya, et al.
Published: (2016-01-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

Profile of etravirine for the treatment of HIV infection
by: Alice Tseng, et al.
Published: (2010-01-01)

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
by: Jesús Troya, et al.
Published: (2017-01-01)

Bioequivalence study of abacavir/lamivudine (600/300-mg) tablets in healthy Thai volunteers under fasting conditions
by: Ekawan Yoosakul, et al.
Published: (2016-02-01)

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
by: Graeme J Moyle, et al.
Published: (2015-01-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
by: Aoran Luo, et al.
Published: (2018-09-01)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
by: McClernon Daniel, et al.
Published: (2009-04-01)

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
by: Cristina Mussini, et al.
Published: (2019-01-01)

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
by: David A Wohl, et al.
Published: (2014-01-01)

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial
by: The Staff
Published: (2014-01-01)

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial.
Published: (2014-01-01)

The Effect of Abacavir on Inflammation and Endothelial Cell Activation in Adults with HIV Infection
by: Hileman, Corrilynn O.
Published: (2010)

Abacavir-induced liver toxicity
by: Maria Diletta Pezzani, et al.
Published: (2016-09-01)

Abacavir: it’s use and hypersensitivity
by: Helena Rabie, et al.
Published: (2009-12-01)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
by: Wang Li-Chun, et al.
Published: (2009-10-01)

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
by: Kunchok Dorjee, et al.
Published: (2021-09-01)

Safety and Efficacy of Fixed Drug Combination Tenofovir, Lamivudine and Efavirenz to Prevent Transmission of HIV
by: Pramendra Sirohi, et al.
Published: (2021-07-01)

Abacavir e o risco cardiovascular
by: Carlos Rego Gonçalves
Published: (2019)

Abacavir methanol 2.5-solvate
by: Phuong-Truc T. Pham
Published: (2009-08-01)